News | June 06, 2022
Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
To address the preventive & primary healthcare delivery gaps in India
Innate to receive $5M milestone payment from AstraZeneca
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Subscribe To Our Newsletter & Stay Updated
